Heat Bio’s shares ignite on Opdivo combination data in NSCLCThe pairing of Heat Biologics’ lead drug HS-110 with Bristol-Myers Squibb’s blockbuster checkpoint inhibitor Opdivo has boosted survival Share XHeat Bio’s shares ignite on Opdivo combination data in NSCLChttps://pharmaphorum.com/news/heat-bios-shares-ignite-on-opdivo-combination-data-in-nsclc/
Roche nabs breakthrough tag for TIGIT cancer immunotherapyRoche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough Share XRoche nabs breakthrough tag for TIGIT cancer immunotherapyhttps://pharmaphorum.com/news/roche-nabs-breakthrough-tag-for-tigit-cancer-immunotherapy/
J&J files lung cancer bispecific amivantamab for FDA approvalJohnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big Share XJ&J files lung cancer bispecific amivantamab for FDA approvalhttps://pharmaphorum.com/news/jj-files-lung-cancer-bispecific-amivantamab-for-fda-approval/
Genprex cancer gene therapy paired with AZ, Merck lung cancer drugsAn experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Share XGenprex cancer gene therapy paired with AZ, Merck lung cancer drugshttps://pharmaphorum.com/news/genprex-cancer-gene-therapy-paired-with-az-merck-lung-cancer-drugs/
FDA sets Feb decision date for Libtayo lung cancer challenge to KeytrudaThe FDA has started a priority review of Regeneron and Sanofi’s checkpoint inhibitor Libtayo in first-line non-small cell Share XFDA sets Feb decision date for Libtayo lung cancer challenge to Keytrudahttps://pharmaphorum.com/news/fda-sets-feb-decision-date-for-libtayos-lung-cancer-challenge-to-keytruda/
FDA grants fast review for AstraZeneca’s Tagrisso in early-stage lung cancerThe FDA has granted a fast review for AstraZeneca’s Tagrisso oncology drug in certain patients with early-stage lung Share XFDA grants fast review for AstraZeneca’s Tagrisso in early-stage lung cancerhttps://pharmaphorum.com/news/fda-grants-fast-review-for-astrazenecas-tagrisso-in-early-stage-lung-cancer/
New data reinforce Keytruda’s dominance in first-line lung cancerFive-year data with Merck & Co’s Keytruda showing that it doubles survival should help the drug fend off Share XNew data reinforce Keytruda’s dominance in first-line lung cancerhttps://pharmaphorum.com/news/new-data-reinforce-keytrudas-dominance-in-first-line-lung-cancer/
Price cut wins NICE OK for AZ’s Tagrisso in untreated lung cancerUK cost-effectiveness watchdog NICE has changed its stance on AstraZeneca’s Tagrisso as a first-line therapy for non-small cell Share XPrice cut wins NICE OK for AZ’s Tagrisso in untreated lung cancerhttps://pharmaphorum.com/news/price-cut-wins-nice-ok-for-azs-tagrisso-in-untreated-lung-cancer/
FDA starts quick review of Merck’s MET-targeting lung cancer drugMerck KGaA could be looking at an early 2021 approval for its MET inhibitor tepotinib in lung cancer Share XFDA starts quick review of Merck’s MET-targeting lung cancer drughttps://pharmaphorum.com/news/fda-starts-quick-review-of-mercks-met-targeting-lung-cancer-drug/
